

DAFTAR PUSTAKA

- AHFS. (2021). *Drug Information*. American Society of Health-System Pharmacists.
- Akbar, M. R., Febrianora, M., & Iqbal, M. (2022). Warfarin Usage in Patients With Atrial Fibrillation Undergoing Hemodialysis in Indonesian Population. *Current Problems in Cardiology*, 101104. <https://doi.org/10.1016/j.cpcardiol.2022.101104>
- Apostolakis, S., Lane, D. A., Buller, H., & Lip, G. Y. H. (2013). Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. *Thrombosis and Haemostasis*, 110(11), 1074–1079. <https://doi.org/10.1160/TH13-07-0552>
- Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., Delling, F. N., Djousse, L., Elkind, M. S. V., Ferguson, J. F., Fornage, M., Jordan, L. C., Khan, S. S., Kissela, B. M., Knutson, K. L., ... On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. (2019). Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. *Circulation*, 139(10). <https://doi.org/10.1161/CIR.0000000000000659>
- Brunton, L., Parker, Keith, blumenthal, donald, & buxton, lain. (2018). *Goodman & Gilman, Manual Farmakologi dan Terapi*. Penerbit Buku Kedokteran EGC.
- Dincer, G. (2022). *Importance of Therapeutic Drug Monitoring for safe and effective drug intake*. 5. <https://doi.org/10.35248/JCCLM.22.05.245>
- DiPiro, J. T. (Ed.). (2020). *Pharmacotherapy: A pathophysiologic approach* (Eleventh edition). McGraw Hill Medical.
- Farsad, B.-F., Abbasinazari, M., Dabagh, A., & Bakshandeh, H. (2016). Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial

- Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study. *Journal of Clinical and Diagnostic Research : JCDR*, 10(9), FC04–FC06. <https://doi.org/10.7860/JCDR/2016/21955.8457>
- Fornas. (2021). *Kmk No. Hk.01.07-menkes-6485-2021 Ttg Formularium Nasional*. <https://doku.pub/documents/kmk-no-hk0107-menkes-6485-2021-ttg-formularium-nasional-nl2z4zwwy218>
- Ganesan, P. (2015). *Characterization of Cardiac Electrogram Signals During Atrial Fibrillation*.
- Hartono, B., hanafy, dicky, Yugo, D., & maharani, erika. (2019). *Pedoman Tata Laksana Fibrilasi Atrium Nonvalvular*. Trans Medical International.
- Heartology. (2022). *ARRHYTHMIA & DEVICE CENTER | HEARTOLOGY*. <https://heartology.id/arrhythmia-device-center>
- Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., Fauchier, L., Filippatos, G., Kalman, J. M., La Meir, M., Lane, D. A., Lebeau, J.-P., Lettino, M., Lip, G. Y. H., Pinto, F. J., ... Zakirov, N. U. (2021). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *European Heart Journal*, 42(5), 373–498. <https://doi.org/10.1093/eurheartj/ehaa612>
- ICD-10. (2019). *ICD-10 Version:2019*. <https://icd.who.int/browse10/2019/en>
- Kim, M. H., Johnston, S. S., Chu, B.-C., Dalal, M. R., & Schulman, K. L. (2011). Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States. *Circulation: Cardiovascular Quality and Outcomes*, 4(3), 313–320. <https://doi.org/10.1161/CIRCOUTCOMES.110.958165>
- Krittayaphong, R., Chantrarat, T., Rojjarekumpai, R., Jittham, P., Sairat, P., & Lip, G. Y. H. (2020). Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry. *Journal of Clinical Medicine*, 9(6), 1698. <https://doi.org/10.3390/jcm9061698>

- Krittayaphong, R., Winijkul, A., Methavigul, K., & Lip, G. Y. H. (2023). Impact of Achieving Blood Pressure Targets and High Time in Therapeutic Range on Clinical Outcomes in Patients With Atrial Fibrillation Adherent to the Atrial Fibrillation Better Care Pathway: A Report From the COOL-AF Registry. *Journal of the American Heart Association*, 12(3), e028463. <https://doi.org/10.1161/JAHA.122.028463>
- Lee, S.-R., Choi, E.-K., Kwon, S., Jung, J.-H., Han, K.-D., Cha, M.-J., Oh, S., & Lip, G. Y. H. (2020). Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage. *Stroke*, 51(2), 416–423. <https://doi.org/10.1161/STROKEAHA.119.028030>
- Medscape. (2023). *Drug Interactions Checker—Medscape Drug Reference Database*. <https://reference.medscape.com/drug-interactionchecker>
- Page, C. P. (2021). *Dale's pharmacology condensed: Clive Page, OBE, PhD, Director, Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science King's College London, London, United Kingdom, Simon Pitchford, BSc, PhD, Sackler Institute of Pulmonary Pharmacology Institute of Pharmaceutical Science King's College London, London, United Kingdom (Third edition)*. Elsevier.
- Pandey, A. K., Xu, K., Zhang, L., Gupta, S., Eikelboom, J., Cook, O., McIntyre, W. F., Lopes, R. D., Crowther, M., Belley-Côté, E. P., & Whitlock, R. P. (2020). Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Thrombosis and Haemostasis*, 120(3), 484–494. <https://doi.org/10.1055/s-0039-3401823>
- Perki. (2012). *Mengenal Kaitan Penyakit Jantung Dengan Penyakit Lain*. Perhimpunan Dokter Spesialis kardiovaskular Indonesia (PERKI).
- Queensland Health. (2016). Guidelines for warfarin management in the community. *State of Queensland (Queensland Health) and the Royal Flying Doctor Service Queensland Section*, 27.
- Rahasto, P., & Chandramin. (2016). *Aritmia Dalam Praktek Sehari-Hari*. Perhimpunan Dokter Spesialis kardiovaskular Indonesia (PERKI).

- Richard, F., Richard A, H., Pamela C, C., Ramadhani, D., Tjahyanto, adhy, & salim, calorina. (2013). *Farmakologi Ulasan Bergambar* (Ed 4). Penerbit Buku Kedokteran ECG.
- Rivera-Caravaca, J. M., Roldán, V., Esteve-Pastor, M. A., Valdés, M., Vicente, V., Lip, G. Y. H., & Marín, F. (2017). Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. *Scientific Reports*, 7(1), 12066. <https://doi.org/10.1038/s41598-017-11683-2>
- Roldán, V., Marín, F., Fernández, H., Manzano-Fernandez, S., Gallego, P., Valdés, M., Vicente, V., & Lip, G. Y. H. (2013). Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a “Real-World” Population With Atrial Fibrillation Receiving Anticoagulant Therapy. *Chest*, 143(1), 179–184. <https://doi.org/10.1378/chest.12-0608>
- Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993). A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy. *Thrombosis and Haemostasis*, 69(03), 236–239. <https://doi.org/10.1055/s-0038-1651587>
- Roveny. (2015). *Antikoagulan untuk Stroke Iskemik Kardioemboli*. 345–349.
- Sekarsari, D. D., Ardianto, P., Kresnadi, E., & Sobirin, M. A. (2021). TIME IN THERAPEUTIC RANGE (TTR) IN ATRIAL FIBRILLATION WITH WARFARIN THERAPY IN SEMARANG, INDONESIA. *DIPONEGORO MEDICAL JOURNAL (JURNAL KEDOKTERAN DIPONEGORO)*, 10(5), 315–319. <https://doi.org/10.14710/dmj.v10i5.30046>
- Shikdar, S., Vashisht, R., & Bhattacharya, P. T. (2022). International Normalized Ratio (INR). Dalam *StatPearls [Internet]*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK507707/>
- Shirazi, A. (2007). International Normalized Ratio (INR). *Gomal Journal of Medical Sciences*, 5.
- Siddiqui, S., Deremer, C., Waller, J., & Gujral, J. (2018). Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin. *Journal of Innovations in Cardiac Rhythm*

Management, 9(12), 3428–3434.
<https://doi.org/10.19102/icrm.2018.091203>

Stambler, B. S. (2013). A new era of stroke prevention in atrial fibrillation: Comparing a new generation of oral anticoagulants with warfarin. *International Archives of Medicine*, 6(1), 46. <https://doi.org/10.1186/1755-7682-6-46>

Vestergaard, A. S., Skjøth, F., Larsen, T. B., & Ehlers, L. H. (2017). The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. *PLOS ONE*, 12(11), e0188482. <https://doi.org/10.1371/journal.pone.0188482>

Waranugraha, Y., Rizal, A., Syaban, M. F. R., Faratisha, I. F. D., Erwan, N. E., & Yunita, K. C. (2021). Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: A systematic review and meta-analysis of real-world evidences. *The Egyptian Heart Journal*, 73(1), 70. <https://doi.org/10.1186/s43044-021-00194-1>

Waugh, A., & Grant, A. (2014). *Ross and Wilson anatomy & physiology in health and illness* (12th edition). Churchill Livingstone Elsevier.

Yuniadi, yoga, tondas, A., hanafy, dicky, hermanto, dony, maharani, erika, munawar, muhammad, & raharjo, sunu. (2014). *PEDOMAN TATA LAKSANA FIBRILASI ATRIUM - PDF Free Download*. Adoc.Pub. <https://adoc.pub/pedoman-tata-laksana-fibrilasi-atrium.html>

Zhu, W., He, W., Guo, L., Wang, X., & Hong, K. (2015). The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. *Clinical Cardiology*, 38(9), 555–561. <https://doi.org/10.1002/clc.22435>